A phase-III trial compares teriflunomide with interferon beta-1a.
Teriflunomide is an FDA-approved oral treatment for relapsing-remitting multiple sclerosis (RRMS) that has demonstrated significant reductions of the annualized relapse rate (ARR) compared with placebo. Now, researchers have conducted the manufacturer-sponsored TENERE trial to compare teriflunomide with another commonly used treatment, subcutaneous interferon beta-1a (IFNβ-1a).
Researchers randomly assigned 324 patients, in a 1:1:1 manner, to IFNβ-1a, teriflunomide 7 mg daily, or teriflunomide 14 mg daily for an average of 60 weeks. The primary outcome was the time to failure, which was the time to the first relapse on treatment or discontinuation of treatment for any reason. The authors chose this outcome with the intent to reflect the effe…